¾ where would the safety features (UID code and ATD) be present on the packaging.
¾ clarifications were asked on the type of diluent used. The company indicated that
normal saline should be used, more specifically 0,9 sodium chloride injection,
insisting on the fact that it must be used for one time dilution, regardless of the
volume of the locally sourced diluent vial.
¾ whether there were any problems storing the vaccine with other vaccines in the ultra
cold freezer. The company stressed that there were no problems as long as the GMP
procedures were respected.
The company noted that it is possible that the final preparation and logistical requirements may
change in light of forthcoming data on dosing, stability, manufacturing and shipping
requirements.
The Members were invited to contact Pfizer directly for further questions of clarifications.
The Members also called for a Q&A to be distributed by the company.